Clinical Trial Update: Study to Evaluate the Safety and Immunogenicity of a 10-valent Pneumococcal Conjugate Vaccine in Preterm Infants [Phase 3]

View source ↗

Summary

A Phase 3 trial evaluating safety and immunogenicity of a 10-valent pneumococcal conjugate vaccine in preterm infants has completed and results were posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Infections of the Respiratory Tract
• Streptococcal Infections

Drugs mentioned

• 10-valent pneumococcal conjugate vaccine (pneumococcal conjugate vaccine (10-valent))

Snippet

Sponsor: GlaxoSmithKline | Conditions: Infections, Streptococcal | Phase 3 | Status: COMPLETED | Results posted: 2018-12-17